The French biotech company Abivax SA reported impressive results from its clinical trials, leading to a remarkable rise in stock prices during premarket trading.
Abivax Clinical Trial Results
Abivax SA announced significant success in its ABTECT clinical trial evaluating obefazimod for ulcerative colitis treatment. The trial demonstrated a 16.4% clinical remission rate, meeting FDA criteria.
Market Reaction to News
Following the announcement, Abivax shares opened at $49.88, a staggering 398.80% increase from the previous close. The market reacted with a substantial spike in trading volume, reflecting heightened investor interest.
Company Prospects and Future Steps
The company plans to submit New Drug Applications to the FDA and EMA in the second half of 2026, contingent on positive ongoing maintenance trial results.
The positive clinical trial results for Abivax represent a significant step forward for the company and open new treatment prospects for ulcerative colitis patients.
